We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics.
Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency and efficacy, which is where we come in. Our suite of immortal MSC lines represent an endless source of therapeutically active EVs, eliminating the need for donor source material. Combined with an in-house chemically defined medium, we can provide improved batch consistency, while reducing cost of goods and reducing regulatory burden.
Our initial target is osteoarthritis, which presents an unprecedented socioeconomic burden as populations age and no disease modifying drugs exist. With our MSC-derived EVs, we have shown that we can exert a strong anti-inflammatory effect, with the added capability of specific cargo delivery.
Our MSC-EV production platform is an agile, versatile means of producing therapeutic EVs for any application at improved consistency.
Company Details
- Employees
- 10
- Founded
- -
- Address
- York, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mesenbio.net
- Keywords
- Biotechnology, Extracellular Vesicles, Exosomes, Mesenchymal Stem Cells, Mesenchymal Stromal Cells, Cell Lines, Osteoarthritis, Regenerative Medicine, Novel Therapeutics, Platform Technologies.
- HQ
- York
Mesenbio Questions
Mesenbio's website is http://www.mesenbio.net
Mesenbio's LinkedIn profile is https://uk.linkedin.com/company/mesenbio
Mesenbio has
10 employees.
View email and phone details for 10
employees at Mesenbio.
Mesenbio's industry is
Biotechnology Research
Mesenbio's top competitors are
Ng Bio,
Bastion Therapeutics,
Diosynvax,
Clinuvel Pharmaceuticals Ltd,
Senya Therapeutics,
Bit.bio,
Scarlet Therapeutics Ltd,
Abselion,
Lightox Ltd,
Cellesce Ltd.
Mesenbio's categories are Biotechnology Research
Mesenbio's founding year is 2021
